Navigation Links
Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
Date:1/31/2008

BONITA SPRINGS, Fla., Jan. 31 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, is pleased to announce the appointment of Mr. Pedro Granadillo to its Board of Directors.

Mr. Granadillo served as Senior Vice President for Eli Lilly and Company ("Lilly") until 2004 when he retired after 34 years of service. He was member of Lilly's Policy Committee, which was comprised of its top seven executives. As Lilly's top human resources, manufacturing and quality executive, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as, a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly's conventional "small-molecule" pharmaceuticals and "large-molecule" biotech therapies.

"Pedro's appointment brings to the Board three decades of industry knowledge and extensive pharmaceutical development and management experience," said Edmundo Muniz, Chief Executive Officer of Tigris. "His past experience and proven track record in corporate management, human resources, manufacturing and quality assurance will be instrumental as we drive our clinical and preclinical programs forward."

"I am excited to be joining Tigris at this important time in the Company's development," said Mr. Granadillo. "I look forward to working with the management team, the Board and the Company's investors in implementing the Company's strategic business plans over the next year and beyond."

Mr. Granadillo is currently a member of the boards of directors of Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Nile Therapeutics, San Francisco, CA. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.

About Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV. Tigris is also developing three novel, targeted small molecule oncology compounds. Tigris' mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients' needs for safe and effective treatments of human illnesses.

Contact: Anne White

Chief Operating Officer

Tigris Pharmaceuticals, Inc.

(239) 444-5400

info@tigrispharma.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
2. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Amylin Pharmaceuticals Reports 2007 Financial Results
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... A man who has struggled to quit smoking, a ... Therapy , was determined to find solutions to his problems – and he did. Now ... is ready to introduce his breakthrough inventions to the world and better people's lives. ...
(Date:2/8/2016)... ... 08, 2016 , ... The Bell Agency, a full service ... of their ongoing community enrichment program. The current campaign fundraises for Angels & ... now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... co-occur frequently. While a significant number of women and men with eating disorders ... trauma itself, that best predicts the development of an eating disorder. , ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest ... products. , Moles are derived from a cluster of melanin when exposed to sunlight. ... places and create a lifetime of embarrassment. Historically, mole removal has involved ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 http://www.researchandmarkets.com/research/x6mkjm/knee ... "Knee Reconstruction Devices Market by Product Type (Primary ... Geography (U.S., Canada, Eu-5, Japan, Bric, Turkey, Indonesia ... report to their offering. --> ... "Knee Reconstruction Devices Market by Product Type ...
(Date:2/8/2016)...  The University of Michigan Health System in ... part of the development of four new operating rooms, ... the U.S. to start using new top-of-the-line neurosurgical imaging ... of neurosurgery. --> Karin Muraszko , ... The BrightMatter technology from Synaptive Medical – a highly ...
(Date:2/8/2016)... DUBLIN , Feb. 8, 2016 /PRNewswire/ ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ... has announced the addition of the ... - Global Forecasts to 2020" report ...
Breaking Medicine Technology: